Stojanović Ivana, Cvjetićanin Tamara, Lazaroski Sandra, Stosić-Grujicić Stanislava, Miljković Djordje
Department of Immunology, Institute for Biological Research Sinisa Stanković, University of Belgrade, Belgrade, Serbia.
Immunology. 2009 Jan;126(1):74-83. doi: 10.1111/j.1365-2567.2008.02879.x. Epub 2008 Jun 20.
Interleukin (IL)-17 is a pro-inflammatory cytokine produced by recently described T helper type 17 (Th17) cells, which have critical role in immunity to extracellular bacteria and the pathogenesis of several autoimmune disorders. IL-6 and transforming growth factor (TGF)-beta are crucial for the generation of Th17 cells in mice, while the production of IL-17 is supported by various cytokines, including IL-23, IL-1beta, IL-21, IL-15 and tumour necrosis factor (TNF)-alpha. In this study, the influence of a multifunctional cytokine, macrophage migration inhibitory factor (MIF), on IL-17 production in mice was investigated. Treatment of lymph node cells (LNCs) with recombinant MIF up-regulated mitogen-stimulated IL-17 expression and secretion. Additionally, LNCs from MIF knockout mice (mif(-/-)) had severely impaired production of IL-17, as well as of IL-1beta, IL-6, IL-23 and TGF-beta. When stimulated with recombinant IL-1beta, IL-23 or TNF-alpha, mitogen-triggered mif(-/-) LNCs were fully able to achieve the IL-17 production seen in wild-type (WT) LNCs, while the addition of IL-6 and TGF-beta had no effect. Finally, after injection of mice with complete Freund's adjuvant, secretion of IL-17 as well as the number of IL-17-positive cells was significantly lower in the draining lymph nodes of mif(-/-) mice in comparison with WT mice. The effect of MIF on IL-17 production was dependent on p38, extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) and Janus kinase 2/signal transducer and activator of transcription 3 (Jak2/STAT3), and not on nuclear factor (NF)-kappaB and nuclear factor of activated T cells (NFAT) signalling. Bearing in mind the contribution of MIF and IL-17 to the pathology of inflammatory and autoimmune disorders, from the results presented here it seems plausible that targeting MIF biological activity could be a valid therapeutic approach for the treatment of such diseases.
白细胞介素(IL)-17是一种促炎细胞因子,由最近发现的17型辅助性T细胞(Th17)产生,Th17细胞在抗细胞外细菌免疫及多种自身免疫性疾病的发病机制中起关键作用。IL-6和转化生长因子(TGF)-β对小鼠Th17细胞的产生至关重要,而IL-17的产生则受到多种细胞因子的支持,包括IL-23、IL-1β、IL-21、IL-15和肿瘤坏死因子(TNF)-α。在本研究中,研究了多功能细胞因子巨噬细胞移动抑制因子(MIF)对小鼠IL-17产生的影响。用重组MIF处理淋巴结细胞(LNCs)可上调丝裂原刺激的IL-17表达和分泌。此外,MIF基因敲除小鼠(mif(-/-))的LNCs产生IL-17以及IL-1β、IL-6、IL-23和TGF-β的能力严重受损。当用重组IL-1β、IL-23或TNF-α刺激时,丝裂原触发的mif(-/-) LNCs能够完全达到野生型(WT)LNCs中所见的IL-17产生水平,而添加IL-6和TGF-β则没有效果。最后,给小鼠注射完全弗氏佐剂后,与WT小鼠相比,mif(-/-)小鼠引流淋巴结中IL-17的分泌以及IL-17阳性细胞的数量显著降低。MIF对IL-17产生的影响依赖于p38、细胞外信号调节激酶(ERK)、c-Jun氨基末端激酶(JNK)和Janus激酶2/信号转导子和转录激活子3(Jak2/STAT3),而不依赖于核因子(NF)-κB和活化T细胞核因子(NFAT)信号传导。考虑到MIF和IL-17对炎症和自身免疫性疾病病理学的作用,从这里给出的结果来看,靶向MIF生物活性可能是治疗此类疾病的一种有效治疗方法。